<DOC>
	<DOCNO>NCT01418521</DOCNO>
	<brief_summary>The purpose randomize controlled trial patient undergoing cardiac surgery show 3rd generation HES ( Hydroxyethyl Starch ) solution - Tetraspan® good term safety effectiveness commonly use albumin base solution volume replacement surgery .</brief_summary>
	<brief_title>Safety Effectiveness Balanced 3rd Generation HES Solution ( Tetraspan® ) After Cardiac Surgery</brief_title>
	<detailed_description />
	<mesh_term>Pharmaceutical Solutions</mesh_term>
	<mesh_term>Hydroxyethyl Starch Derivatives</mesh_term>
	<criteria>Written informed consent must obtain subject his/her legal guardian assessment perform . Male Female subject , 18 year old . Any elective cardiac surgery Subjects impair liver function define elevated level ALT AST 100 U/L . Hyperhydration state ( e.g . pulmonary edema , congestive heart failure ) . Renal failure creatinine blood level &gt; 2.5 mg/dL eGFR &lt; 30 ml/min ( calculate use DMRD formula ) . Oliguria ( UO &lt; 0.5ml\kg\hr ) anuria ( related hypovolemia ) 12 hour . Current Intracranial hemorrhage . Current , hard balance hyperkalemia . Severe hypernatremia severe hyperchloremia . Known hypersensitivity hydroxyethyl starch excipients .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>August 2011</verification_date>
	<keyword>Cardiac surgery</keyword>
	<keyword>Balanced 3rd generation Hydroxyethyl starch</keyword>
	<keyword>Tetraspan</keyword>
	<keyword>Ringer-albumin</keyword>
</DOC>